Business
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Generated $0.8M of Cash from Operating Activities in Q4 2023 Recorded Lowest Quarter of Non-GAAP Operating Loss Since Inception, Non-GAAP Operating Loss for
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"\n\nGenerated $0.8M of Cash from Operating Activities in Q4 2023\n\n\n\nRecorded Lowest Quarter of Non-GAAP Operating Loss Since Inception, Non-GAAP Operating Loss for Q4 is $3.7 Million, an Improvement of $2 Million Compared to Q3\n\n\n\nFull Year 2023 Operating Expense of $163.9 Million in Alignment with Guidance Range of $160 Million to $165 Million\n\n\n\nGlobal Net Revenue Record of $61.0 Million for the Fourth Quarter and $202.1 Million Full Year 2023, Representing 40% and 36% Growth Over the Prior Year; These Results Are Unchanged from the Preliminary Results Reported on January 16th, 2024 \n\n\n\nCompany Updates Mid-Term Guidance and Expects to Achieve Profitability1 for the Fourth Quarter of 2024 and Full Year 2025\n\n\n\n NEWPORT BEACH, Calif.--(BUSINESS WIRE)--\nEvolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its financial results for the fourth quarter and full year ended December 31, 2023.\n\n\n“2023 was a defining year for Evolus. We achieved record market share as the fastest growing toxin in the U.S. for the third consecutive year2, expanded our portfolio globally with the addition of an innovative late-stage line of facial fillers, and delivered continued improvement in operating income performance,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We expect to be profitable1 for the fourth quarter of 2024 and the full year 2025.”\n\n\n“As we enter 2024, we are reiterating our full year net revenue guidance of $255 million to $265 million, which represents 31% growth at the top end of the range. Looking beyond 2024, we remain excited about both the continued expansion of our U.S. and International business with the Jeuveau® and Nuceiva® brands, as well as the introduction of our highly synergistic Evolysse™ and Estyme® dermal filler line, further increasing our market penetration and driving toward our total net revenue goal of at least $700 million by 2028.”\n\n\nFourth Quarter and Full Year 2023 Highlights and Recent Developments\n\n\n\nThe company’s key performance indicators demonstrated continued strong momentum during the fourth quarter.\n\n\nAccounts purchasing Jeuveau® increased by a record high of more than 840 in the fourth quarter. This is 20% above the year-to-date quarterly ...